Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients.
INTRODUCTION Survival in metastatic castration-resistant prostate cancer (mCRPC) patients remains limited and treatment is complicated by tumor heterogeneity. As antibody-based therapeutics emerge, identifying actionable antigen targets and patient subgroups most likely to benefit is essential. MATERIALS & METHODS Ge...